Abstract: Described herein are oral compositions comprising an extract obtained from Arialaceae, Zingiberaceae, Lamiaceae, Fabaceae, Solanaceae, Punicaceae. Asteraceae or mixtures thereof; Their uses for alleviating dry mouth is also described.

Abstract: The present invention relates to a class of fragrance precursor compounds comprising one or more of the compounds derived from the reaction of X—OH and an aldehyde or ketone, said fragrance precursor compounds being of the formula X—O—C(R)(R*)(OR**) wherein R is a C6-24 alkyl group, a C6-24 aralkyl group or a C6-24 alkaryl group; R* is H or a C6-24 alkyl group, a C6-24 aralkyl group or a C6-24 alkaryl group; R** is H or X; X—O representing a moiety derived from X—OH, and wherein X—OH is a compound selected from the group consisting of surfactants, fabric softeners, softener precursor ester amines, softener precursor amido amines, hair conditioners, skin conditions, saccharides and polymers. In a second aspect it relates to a method of preparing such precursors. Further the invention relates to compositions, comprising the precursor of the invention.

Abstract: A white, color-stable anti-aging emulsion formula containing CoQ10 and/or vanillin. The amount of vanillin can be adjusted to provide light or dark tanning of the skin. Lime oil and lime juice form a preferred emulsion foundation.

Abstract: Disclosed are topical skin compositions and corresponding methods of their use that include an extract from Artabotrys hexapetalus, an extract from Sassafras tzumu, and an extract from Prunus salicina.

Abstract: The present invention relates to a cosmetic composition for making up and/or caring for keratin materials, in the form of an oil-in-water solid emulsion, comprising, in a physiologically acceptable medium: —from 4.0% to 8.0% by weight, relative to the total weight of the composition, of at least one fatty alcohol, —from 1.0% to 3.0% by weight, relative to the total weight of the composition, of at least one solid linear ester, —from 2.5% to 6.0% by weight, relative to the total weight of the composition, of at least one non-ethoxylated glyceryl stearate, and —from 0.25% to 0.50% by weight, relative to the total weight of the composition, of sodium polyacrylate.

Abstract: A white, color-stable, stain-free emulsion formulation containing vanillin for sunless tanning. The amount of vanillin can be adjusted, from about 1% up to about 45%, to provide light or dark tanning of the skin. Lime oil and lime juice form a preferred white emulsion foundation.

Abstract: The present invention relates generally to compositions for topical application to the skin which comprise at least one DICKKOPF-1 expression modulator and the use of such compositions to provide benefits to the skin, including but not limited to lightening or darkening skin; treating hyper or hypopigmented skin; increasing or decreasing skin thickness; reducing or increasing skin hirsuteness; and/or changing skin phenotype from non-palmoplantar to palmoplantar.

Abstract: Aqueous polymer solutions are described which have been stabilized with a preservative mixture of 0.01 to 0.2% by weight of ethylhexylglycerol, 0.001 to 0.01% by weight of 2-methylisothiazolinone and 0.05 to 0.5% by weight of phenoxyethanol. The stabilized polymer solutions are suitable for cosmetic preparations, such as skincare and hair care compositions, products of decorative cosmetics and cosmetic cleaning products.

Abstract: Aqueous free-flowing surfactant compositions having non-Newtonian shear thinning properties are disclosed. These stable compositions include both cationic and anionic surfactants and can suspend water-insoluble particles or partially insoluble components.

Abstract: The present invention is directed to a composition for hydrating keratinous substrates such as skin, hair and nails, the composition containing: (a) greater than 10% by weight of glycerin; (b) at least one C3-C8 alkanediol, other than glycerin; (c) an emollient mixture comprising shea butter and squalane; (d) at least one surfactant; and (e) water, all weights based on the total weight of the composition.

Abstract: Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.

Abstract: The present invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which in particular can have a number-average molecular weight of ?400 g/mol and a mean OH functionality of from 2 to 6, as component B) an amino-functional compound of the general formula (I) in which X is an organic radical containing a secondary amino function, Y is an organic radical that contains a tertiary amino group and does not contain Zerewitinoff-active hydrogen, R1 is a CH2—COOR3 radical in which R3 is an organic radical that does not contain Zerewitinoff-active hydrogen, a linear or branched C1- to C4-alkyl radical, a cyclopentyl radical, a cyclohexyl radical or H, R2 is an organic radical that does not contain Zerewitinoff-active hydrogen, a is 1 or 2, b is 1 or 2, and a+b=2 or 3, for stemming the escape of blood, and to a metering system for the polyurea system according to the invention.

Abstract: The subject of the present invention is yarns, fibers or filaments and also a textile article and a medical device obtained from said yarns, for improving skin cicatrization, in particular by activating collagen synthesis at the surface of the injured skin. The yarns, fibers or filaments of the invention comprise a polymeric matrix and inorganic fillers, uniformly dispersed in the polymeric matrix, having properties of absorption and/or of emission in the 2-20 ?m far-infrared region.

Abstract: Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.

Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.

Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Abstract: Disclosed are therapeutic methods for ex-vivo activation of immune cells from a cancer patient for the purpose of inducing tumor regression and/or suppressing metastasis and/or tumor recurrence. In one embodiment mononuclear cells of a patient are isolated from peripheral blood and activated by a combination of innate immune system activators together with means allowing for T cell activation.

Abstract: The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.

Abstract: In one example, the present invention comprises a deliberate insult or the recognition that an insult has occurred in a patient, which insult induces an immune recognition event. The T cell repertoire is catalogued from samples of the patient's lymphocytes from before and after the insult in order to detect and sequence the TCR alpha and beta loci of highly expanded T cell clonotypes. In some examples, this information is used in turn to generate autologous T cells or to create autologous genetically-engineered T cells, either of which include TCR sequences that target the individual's disease or injury, resulting in cure or amelioration of symptoms.

Abstract: The present invention provides methods of treating various disorders associated with mitochondrial dysfunction, including but not limited to metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, and diseases of aging.

Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.

Abstract: It is disclosed a method for the treatment of HBV infection or HBV/HDV co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.

Abstract: A compound is selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of selected from the structural formulae depicted in FIG. 1 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic acids and/or vectors. Finally, the present invention relates to the uses of said polypeptide, variants thereof, nucleic acid sequences, vectors and host cells, in particular for the treatment or prophylaxis of a subject infected by or exposed to Staphylococci.

Abstract: A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.

Abstract: The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications.

Abstract: One aspect of the present disclosure relates to a method for modulating uterine function in a mammal. One step of the method includes placing a therapy delivery device into direct contact with a spinal cord target associated with uterine function. Next, the therapy delivery device is activated to deliver a therapy signal to the spinal cord target in an amount and for a time sufficient to effect a change in sympathetic and/or parasympathetic activity in the mammal and thereby modulate uterine function.

Abstract: The invention relates to tendon stem cells useful for treating a variety of diseases and condition, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation by use of biglycan and/or fibromodulin.

Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.

Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.

Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.

Abstract: A major risk factor for ischemic heart disease is advanced age. In adult bone marrow and other tissues, the number and function of stem cells decline with aging. Telomerase reverse transcriptase (TERT) is a nuclear protein that decreases senescence. Myocardin (MYOCD) is a transcription factor for myogenesis. Thus a method is provided for the simultaneous delivery of the telomerase reverse transcriptase (TERT) and myocardin MYOCD genes that resuscitates mesenchymal stromal cells (MSCs) from aged adipose and bone marrow tissues by increasing their capacity for survival, proliferation, and differentiation. TERT+/MYOCD+ MSCs restores a capacity for repairing ischemic tissues via improved blood flow and revascularization.

Abstract: The present application discloses a recombinantly made protein construct that preferentially forms multimers.

Abstract: A method for liver protection of a mammal is provided and includes administering an effective amount of isolated Lactobacillus plantarum CMU995 thereto. Providing a new use of Lactobacillus plantarum CMU995, which is deposited at the Food Industry Research and Development Institute (FIRDI) in Taiwan under accession number BCRC 910472 and in the German Collection of Microorganisms and Cell Cultures (DSMZ) under accession number DSM 23780.

Abstract: The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

Abstract: The present invention relates to a composition having antioxidant activity. Furthermore, the present invention relates to probiotic bacteria having antioxidant activity and the use thereof.

Abstract: Methods for treating blood. The methods comprise obtaining whole blood from a donor, mixing the whole blood with a red blood cell enhancement composition, and incubating the mixture of whole blood and red blood cell enhancement composition. The method can be performed at a time proximate to the time of obtaining blood from the donor, or after the blood has been stored for a period of time. The method rejuvenates red blood cells.

Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.

Abstract: Compositions and methods for treating wounds are provided. The compositions include cyclic analogues of histatin (5).

Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.

Abstract: The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications.

Abstract: The invention relates to a method for eliminating a biofilm of microorganism preexisting on an inert surface, characterized in that one subjects said biofilm to a cocktail of microorganisms comprising at least strains said to be “swimming” able to cross said biofilm in the plane and in the thickness, and one subjects said biofilm to at least one antimicrobial product directed against at least one microorganism of the biofilm to be eliminated.

Abstract: Provided are a PEGylated analogue protein of canine urate oxidase, preparation method and use thereof. The analogue protein of canine urate oxidase is a canine urate oxidase, or a chimeric protein comprising part of the amino acid sequence of a canine urate oxidase and part of the amino acid sequence of a human urate oxidase, or a mutant protein thereof. The PEGylated analogue protein of canine urate oxidase and pharmaceutical compositions thereof according to the present invention can be used for the prevention and/or treatment of hyperuricemia and chronic gout.

Abstract: The present invention provides hyperactive piggyBac transposons, in particular hyperactive piggyBac transposons from Trichoplusia ni (cabbage looper moth) that transpose at a higher frequency than wildtype. The invention also features integration defective piggyBac transposons. The piggyBac transposons and transposases can be used in gene transfer systems for stably introducing nucleic acids into the DNA of a cell. The gene transfer system can be used in methods, for example, but not limited to, gene therapy, insertional mutagenesis, or gene discovery.

Abstract: A pharmaceutical composition for treating depression and method for preparation thereof is provided. The pharmaceutical composition includes Radix Ginseng, Radix Glycyrrhizae, and/or their aqueous or alcoholic extract. Fructus Jujubae or their aqueous or alcoholic extract can also be included in the pharmaceutical composition.

Abstract: A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.

Abstract: Methicillin-resistant (MRSA) and multi-drug resistant strains of Staphylococcus aureus are becoming increasingly prevalent in both human and veterinary clinics. S. aureus-causing bovine mastitis yields high annual losses to the dairy industry. Treatment of mastitis by broad range antibiotics is often not successful and may contribute to development of antibiotic resistance. Bacteriophage endolysins are a promising new source of antimicrobials. The endolysin of prophage ?SH2 of Staphylococcus haemolyticus strain JCSC1435 (?SH2 lysin) shows lytic activity against live staphylococcal cells. Deletion constructs were tested in zymograms and turbidity reduction assays to evaluate the contribution of each functional module to lysis. The CHAP domain exhibited three-fold higher activity than the full length protein. Activity was further enhanced in the presence of bivalent calcium ions.

Abstract: The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.

Abstract: Methods for treating a subject for a parasympathetic bias mediated condition are provided. Aspects of the methods include modulating at least a portion of the subject's autonomic nervous system to increase the sympathetic/parasympathetic activity ratio in a manner effective to treat the subject for the parasympathetic bias mediated condition. In some instances, the subject is known to have parasympathetic bias. Also provided are devices that find use in practicing various embodiments of the methods.